At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 26 enrolled
Drug / intervention
BGJ398drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Multicenter, Open-label Study of BGJ398 in Patients With Recurrent Resectable or Unresectable Glioblastoma
In Brief
A Phase 2 clinical trial evaluating BGJ398 for Recurrent Glioblastoma or Other Glioma Subtypes. Completed, enrolled 26 participants across 17 sites in 6 countries.
Detailed Summary
This is an open-label non-randomized, multicenter, phase II study of BGJ398 administered to adult patients with histologically confirmed GBM and/or other glioma subtypes with FGFR1-TACC1, FGFR3-TACC3 fusion and/or activating mutation in FGFR1, 2 or 3.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesAustralia, Belgium, Netherlands, Spain, Switzerland, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedNov 2013
Enrollment StartDec 2013
Primary CompletionOct 2018
TodayJul 2026
First PostedNov 5, 2013
Enrollment StartDec 9, 2013
Primary CompletionOct 3, 2018
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 12.7 years ago
Interventions
BGJ398drug
Capsule for oral use.